Advances and challenges in the prevention and treatment of Alzheimer's disease

Pharmaceutical Research

Volumn 15, Issue 3, 1998, Pages 386-398

  Brinton, Roberta Diaz ^a   Yamazaki, Rose S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Anti inflammatories; Anti xodiants; Cholinergic therapies; Estrogen replacement therapy; Nerve growth factor

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID BETA PROTEIN; ANTIESTROGEN; ANTIINFLAMMATORY AGENT; ANTIMALARIAL AGENT; ANTIOXIDANT; AZATHIOPRINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CONJUGATED ESTROGEN; CYCLOPHOSPHAMIDE; ESTRADIOL; ESTROGEN; GESTAGEN; IBUPROFEN; METHOTREXATE; NERVE GROWTH FACTOR; NOOTROPIC AGENT; PREDNISONE;

ALZHEIMER DISEASE; COGNITION; DEMENTIA; ESTROGEN THERAPY; GENE THERAPY; GENETIC LINKAGE; HEALTH CARE COST; HUMAN; INSTITUTIONALIZATION; MEMORY; NERVE CELL LESION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PRIORITY JOURNAL; REVIEW; SENILE PLAQUE; UNITED STATES;

ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; CHOLINERGIC AGONISTS; DRUG COMBINATIONS; ESTROGEN REPLACEMENT THERAPY; GENE THERAPY; HUMANS; PROGNOSIS;

EID: 0031924755     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011963929012     Document Type: Review

References (91)

1. V. W. Henderson. Estrogen replacement therapy for the prevention and treatment of Alzheimer's disease. CNS Drugs In press. (1997).
2. S. Solodkin and G. W. Van Hoesen. Neuropathology and functional anatomy of Alzheimer's disease. In: Pharmacological Treatment of Alzheimer's Disease. J. D. Brioni & M. W. Decker, editors. Wiley-Liss, N. Y., N. Y. 151-177 (1997).
3. D. A. Snowdon, L. H. Greiner, J. A. Mortimer, K. P. Riley, P. A. Greiner, and W. R. Markesbery. Brain infarction and the clinical expression of Alzheimer disease: The nun study. JAMA 277:813-817 (1997).
4. S. J. Birge. The role of estrogen in the treatment of Alzheimer's disease. Neurology 48:S36-S41 (1997).
5. W. Roush. Live long and prosper? Science 273:42-46 (1996).
6. P. J. Whitehouse. Alzheimer's disease: An international public health problem-clinical goals, strategies, and outcomes. In: Pharmacological Treatment of Alzheimer's Disease. J. D. Brioni and M. W. Decker, editors. Wiley-Liss, N. Y., N. Y. 331-343 (1997).
7. C. Holden. New populations of old add to poor nations' burdens. Science 273:46-48 (1996).
8. R. D. Brinton, P. Proffitt, J. Tran, and R. Luu. Equilin, a principal component of the estrogen replacement therapy, Premarin, increases the growth of cortical neurons via an NMDA receptor dependent mechanism. Experimental Neurology 147:211-220 (1997).
9. S. Shumaker and S. Rapp. Hormone replacement therapy in dementia prevention: The women's health initiative memory study. Neurobiol. of Aging 17:S34 (1996).
10. R. D. Brinton, J. Tran, P. Profitt, and M. Kahil. 17 β-Estradiol increases the growth and survival of cultured cortical neurons. Neurochemical Research 22:1339-1351 (1997).
11. C. Behl, T. Skutella, F. Lezoualc'h, A. Post, M. Widmann, C.J. Newton, and F. Holsboer. Neuroprotection against oxidative stress by estrogens: Structure-activity relationship. Molecular Pharmacology 51:535-541 (1997).
12. Y. Goodman, A. J. Bruce, B. Cheng, and M. P. Mattson. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J. of Neurochemistry 66:1836-1844 (1996).
13. VN Luine. Estradiol increases acetyltransferase activity in specific basal forebrain nuclei and projection areas of the female rat brain. Exp. Neurology 89:484-490 (1985).
14. O. Rabbani, K-S. Panickar, G. Rajakumar, M-A. King, N. Bodor, E-M Meyer, and J-W. Simpkins. 17 beta-estradiol attenuates fimbrial lesion-induced decline of ChAT-immunoreactive neurons in the rat medial septum. Exp. Neurology 146:179-86 (1997).
15. M. Singh, E. M., Meyer, W. J., Millard, and J. W. Simpkin. The effect of ovariectomy and estradiol replacement on brain-derived neurotrophic factor messenger ribonucleic acid expression in cortical and hippocampal brain regions of the female Sprague-Dawley rats. Endocrinology 136:2320-2324 (1995).
16. C. D., Toran-Allerand, R. C., Miranda, W. D., Benthamn, F., Sohrabjio, T. J., Brown, R. B. Hocber, and N. J. MacLusky. Estrogen receptors colocalize with low affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc. Natl. Acad. Sci., USA 89:4668-4672 (1992).
17. R. B. Gibbs, and D. W. Pfaff. Effects of estrogen and fimbria/ fornix transection on p75NFGR and ChAT expression in the medial septum and diagonal band of Broca. Exp. Neurol. 116:23-39 (1992).
18. F., Sohrabjio, R. C. Miranda, and C. D. Toran-Allerand. Estrogen differentially regulates estrogen and nerve growth factor receptor mRNAs in adult sensory neurons. J. Neurosci. 14:459-471 (1994).
19. R. C., Miranda, F. Sohrabjio, and D. Toran-Allerand. Interactions of estrogen with the neurotrophins and their receptors during neural development. Hormones and Behavior 28:367-375 (1994).
20. M. J., Knapp, D. S., Knopman, P. R., Solomon et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 271:985-991 (1994).
21. R. D., Brinton, M. Montoya, and D. Hsieh. Premarin increases the growth of neurons from the cerebral cortex. Soc. for Neurosci. Absts. 22:299.3 (1996).
22. R. D., Brinton, M., Muhammad, D. Hsieh, and E. Chen. The estrogen replacement therapy, Premarin, increases neuronal survival and protects neurons against oxidative damage: Implications for Alzheimer's disease. Soc. for Neurosci. Absts. 23:20.5 (1997).
23. J., Xua, X. Xiea, R. D. Brinton, and T. W. Berger. Direct enhancement of NMDA receptor-mediated EPSPs by 17 β-estradiol in hippocampal CA1. Soc. For Neurosci. Absts. 23(2)818.5 (1997).
24. P. S., Green, K. E., Gridley, and J. W. Simpkins. Estrogen receptor-independent neuroprotection by estratrienes: A novel interaction with glutathione. In press (1997).
25. P. S., Green, K., Gordon, and J. W. Simpkins. Phenolic A ring requirement for the neuroprotective effects of steroids. J. Steroid Biochem. Mol. Biology. In press (1997).
26. R. D. Brinton. Estrogen Induction of rapid changes in the growth of cultured hippocampal nerve cells. Molecular and Cellular Neurosciences 4:36-46 (1993).
27. K. Paech, P. Webb, G. G. J. M. Kuiper, S. Nilsson, J-A. Gustafsson, P. J. Kushner, and T. S. Scanian. Differential ligand activation of estrogen receptors ERalpha and ERbeta at API Sites. Science. 277:1508-1510 (1997).
28. M., Byers, G. J. M., Kuiper, J. A., Gustafsson, and O. K. Park-Sarge. Estrogen receptor-beta mRNA expression in rat ovary: Down regulation by gonadotropins Molecular Endocrinology 11:172-182 (1997).
29. G. G. J. M., Kuiper, E., Enmark, M., Pelto-Huikko, S., Nilsson, and J. A. Gustafsson. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93:5925-5930 (1996).
30. K. S. Korach. Insights from the study of animals lacking functional estrogen receptor. Science 266:1524-1527 (1994).
31. G. G. J. M. Kuiper, B. Carlsson, K. Grabdien, E. Enmark, J. Haggblad, S. Nilsson, and J. A. Gustafsson. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors a and β. Endocrinology 138: 863-870 (1997).
32. X., Li, P., Schwartz, and E. Rissman. Distribution of estrogen receptor-beta-like immunoreactivity in rat forebrain. Neuroendocrinology 66:63-67 (1997).
33. D. J. Grainger and J. C. Metcalfe. Tamoxifen: teaching an old drug new tricks? Nature Med 2:381-385 (1996).
34. J. A., Katzenellenbogen, B. W., O'Malley, and B. S. Katzenellenbogen. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell-and promoter-specific action of these hormones. Molec Endocrinology 10: 119-131 (1996).
35. K. F. H. Grandien, A. Berkenstam, S. Nilsson, and I. A. Gustafsson. Localization of Dnase I hypersensitive sites in the human oestrogen receptor gene correlates with the transcriptional activity of two differentially used promoters. J. Mol Endocrinology 10:269-277 (1993).
36. S., Makela, V. I. Davis, W., Tally, J., Korkman, L., Salo, R., Vihko, R., Santti, and K. Korach, Dietary estrogens act through estrogen receptor-mediated processes and show no antiestrogenicity in cultured breast cancer cells. Environ Health Perspect 102:572-581 (1994).
37. H., Adlercreutz, H., Markkanen, and S. Watanabe, Plasma concentration of phyto-estrogens in Japanese men. Lancet 342:1209-1210 (1993).
38. C. Ezzell. Evolutions: Alzheimer's disease. J. NIH Research. 7:108 (1995).
39. D. B., Lubahn, J. S., Moyer, T. S. Golding, J. F. Couse, K. S. Korach, and O. Smithies. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci USA 90:11162-11166 (1993).
40. P. L. McGeer and J. Rogers. Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology. 42:447-449 (1992).
41. P. L. McGeer, J. Rogers, and E. G. McGeer. Neuroimmune mechanisms in Alzheimer disease pathogenessis. Alzheimer Disease and Associated Disorders. 8:149-158 (1994).
42. P. L., McGeer, E., McGeer, J., Rogers, and J. Sibley. Anti-inflammatory drugs and Alzheimer disease. Lancet.335:1037 (1990).
43. J. C. S. Breitner. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annual Review of Medicine. 47:401-411 (1996).
44. J. C. S. Breitner, K. A. Welsh, B. L. Plassman, W. M. McDonald, M. J. Helms, and J. C. Anthony. Inverse association of anti-inflammatory treatments and Alzheimer's disease: Initial results of a co-twin control study. Neurology. 44:227-231 (1994).
45. J. B. Rich, D. X. Rasmusson, M. F. Folstein, K. A. Carson, C. Kawas, and J. Brandt. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology. 45:51-55 (1995).
46. J, Rogers, L. C. Kirby, S. R. Hempelman, et. al. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 43:1609-1611 (1993).
47. P. S., Aisen and K. L., Davis. Inflammatory mechanisms in Alzheimer's disease: Implications for therapy. Am J. Psychiatry 151:1105-1113 (1994).
48. J. C. S. Breitner. Inflammatory Processes and antiinflammatory drugs in Alzheimer's disease: A current appraisal. Neurobiology of Aging. 17:789-794 (1996).
49. S. D., Yan, X., Chen, J., Fu, M., Chen, H., Zhu, A., Roher, T., Slattery, L., Zhao, M., Nagashima, J., Morser, A., Migheli, P., Nawroth, D., Stem, and A. M., Schmidt. RAGE and amyloidbeta peptide neurotoxicity in Alzheimer's disease. Nature 382:685-91 (1996).
50. J., El Khoury, S. E., Hickman, C. A., Thomas, L., Cao, S. C., Silverstein, and J. D., Loike. Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature 382:716-9 (1996).
51. S. W. Barger and A. D. Harmon. Microglial activation by Alzheimer amyloid precursor protein and modulation by apoliprotein E. Nature. 388:878-881 (1997).
52. S. D., Yan, H., Zhu, J., Fu, S. F., Yan, A., Roher, W. W., Tourellott, T., Rajavashisth, X., Chen, G. C., Godman, D., Stern, and A. M. Schmidt. Amyloid-β peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophagecolony stimulating factor: A proinflammatory pathway in Alzheimer disease. Proc. Natl. Acad. Sci. USA 94:5296-5301 (1997).
53. P. S., Aisen. Inflammation and Alzheimer's disease. Molecular and Chemical Neuropathology 28:83-88 (1996).
54. J. Rogers, S. Webster, L-F. Lue, L. Brachova, W. H. Civin, M. Emmerling, B. Shivers, D. Walker, and P. McGeer. Inflammation and Alzheimer's disease pathogenesis. Neurobiology of Aging 17:681-686 (1996).
55. C. Behl, F. Lezoualc'h, T. Trapp, M. Widmann, T. Skutella, and T. Holsboer. Glucocorticoids enhance oxidative stress-induced cell death in hippocampal neurons in vitro. Endocrinology 138:101-106 (1997).
56. th edition. A. G.Goodman, T. W. Rail, A. S. Nies, P. Tayor, editors. Pergamon Press, 638-681 (1990).
57. S., Vasan, X., Zhang, A., Kapurniotu, J., Bernhagen, S., Teichberg, J., Basgen, D., Wagle, D., Shih, I., Terlecky, R., Bucala, A., Cerami, J., Egan, and P., Ulrich. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 382:275-8 (1996).
58. M. A., Smith, G., Perry, P. L., Richey, L. M., Syre, V. E., Anderson, M. F., Beal, and N., Kowall. Oxidative damage in Alzheimer's. Nature 382:120-1 (1996).
59. K. V., Subbarao, J. S., Richardson, and L. C., Ang. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J. of Neurochemistry 55:342-345 (1990).
60. B. N, Ames, M. K., Shigenaga, and T. M., Hagen. Oxidants, antioxidants, and the degenerative diseases of aging. Proc. Natl. Acad. Sci. USA 90:7915-7922 (1993).
61. P. S. Aisen and K. L. Davis. The search for disease-modifying treatment for Alzheimer's disease. Neurology 48:S35-S41 (1997).
62. M. Sano, C. Ernesto, R. G. Thomas, M. R. Klauber, K. Schafer, M. Grundman, P. Woodbury, J. Growdon, C. W. Cotman, E. Pfeiffer, L. S. Schneider, and L. J. Thal. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The New England Journal of Medicine 336:1216-1222 (1997).
63. D. M. Bowen. Alzheimer's disease. In: The Molecular Basis of Neuropathology. A. N. Davison and R. H. S. Thompson, eds. Edward Arnold. London, England 649-665 (1981).
64. L. Schneider. New therapeutic approaches to Alzheimer's disease. J. Clin Psychiatry 57:30-35 (1996).
65. E. Giacobini. Cholinometric therapy of Alzheimer's disease: does it slow down deterioration? In: Recent Advances in the Treatment of Neurodegenerative Disorders and Cognitive Dysfunction. G. Racagni, N. Brunello, and S. Z. Langer, eds. Karger. Basel, Switzerland 7:51-57 (1994).
66. F. Hefti. Development of effective therapy for Alzheimer's disease based on neurotrophic factors. Neurobiology of Aging 15:S193-S194 (1994).
67. A. J. Dekker, J. Winkler, J. Ray, L. J. Thai, and F. H. Gage. Grafting of nerve growth factor-producing fibroblasts reduces behavioral deficits in rats with Llesions of the nucleus basalis magnocellularis. Neuroscience 60:299-309 (1994).
68. A. Martinez-Serrano, W. Fischer, and A. Bjorklund. Reversal of age-dependent cognitive impairments and cholinergic neuron atrophy by NGF-secreting neural progenitors grafted to the basal forebrain. Neuron 15:473-484 (1995).
69. T., Nabeshima, A., Nitta, K., Fuji, T., Kameyama, and T. Hasegawa. Oral administration of NGF synthesis stimulators recovers reduced brain NGF content in aged rats and cognitive dysfunction in basal-forebrain-lesioned rats. Gerontology 40:46-56 (1994).
70. R., Clark and A., Goate. Recent developments in the genetics of Alzheimer's disease. In: Pharmacological Treatment of Alzheimer's Disease. J. D. Brioni and M. W. Decker, editors. Wiley-Liss, N.Y., N.Y 193-215 (1997).
71. D. J., Selkoe. Alzheimer's disease: a central role for amyloid. J. of Neuropathology and Experimental Neurology 53:438-47 (1994).
72. J. K., Teller, C., Russo, L. M., DeBusk, G., Angelini, D., Zaccheo, F., Dagna-Bricarrelli, P., Scartezzini, S., Bertolini, D. M., Mann, M., Tabaton, and P., Gambetti. Presence of soluble amyloid beta peptide precedes amyloid plaque formation in Down's Syndrome Nature Medicine 2:93-5 (1996).
73. J. Li, M. Xu, H. Zhou, J. Ma, and H. Potter. Alzheimer presenilins in the nuclear membrane, interphase kinetochores, and centrosomes suggest a role in chromosome segregation. Cell. 90:917-927 (1997).
74. E. Corder, A., Saunders, W., Strittmatter, et al., Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-923 (1997).
75. D. A., Evans, L. A., Beckett, T. S., Field, L., Feng, M. S., Albert, D. A., Bennett, B., Tycko, and R., Mayeux. Apolipoprotein E ∈4 and incidence of Alzheimer disease in a community population of older persons. JAMA 277:822-824 (1997).
76. D., Blacker, J. L., Haines, L., Rodes, H., Terwedow, R. C. P., Go, L. E., Harrell, R. T. Perry, S. S., Bassett, G., Chase, D., Meyers, M. S., Albert, and R. Tanzi. ApoE-4 and age at onset of Alzheimer's disease. Neurology 48:139-147 (1997).
77. H., Payami, G. D., Schellenberg, MS., Zareparsi, M. D., Kaye, G. J., Sexton, M. A., Head, S. S., Matsuyama, M. D., Jarvik, B., Miller, D. Q., McManus, T. D., Bird, M. D., Katzman, L., Heston, D., Norman, and G. W. Small. Evidence for association of HLA-A2 allele with onset age of Alzheimer's disease. Neurology 49:512-518 (1997).
78. C. L., Lendon, F., Ashall, and A. M. Goate. Exploring the etiology of Alzheimer disease using molecular genetics JAMA 227:825-31 (1997)
79. K., Chandrasekaran, T., Giordano, D. R., Brady, J., Stoll, L. J., Martin, and S. I. Rapoport. Impairment in mitochodrial cytochrome oxidase gene expression in Alzheimer disease. Brain Research. Molecular Brain Research 24:336-40 (1994).
80. K., Chandrasekaran, K, Hatanpaea, S. I., Rapoport, and D. R. Brady. Decreased expression of nuclear and mitochondrial DNA-encoded genes of oxidative phosphorylation in association neocortex in Alzheimer disease. Brain Research. Molecular Brain Research 44:99-104 (1997).
81. W. D. Parker, Jr., N. J., Mahr, C. M., Filley, J. K., Parks, D., Hughes, D. A., Young, and C.M., Cullum. Reduced platelet cytochrome c oxidase activity in Alzheimer's disease. Neurology 44:1086-90 (1994).
82. R. E., Davis, S., Miller, C., Herrnstadt, S. S., Ghosh, E., Fahy, L. A., Shinobu, D., Galasko, L. J., Thai, M. F., Beal, N., Howell, and W. D., Parker, Jr. Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 94:4526-31 (1997).
83. M. P. Mattson. Mother's legacy: mitochondrial DNA mutations and Alzheimer's disease. Trends in Neurosciences 20:373-375 (1997).
84. S. G., Post, P. J., Whitehouse, R. H., Binstock, T. D., Bird, S. K., Eckert, L. A., Farrer, L. M., Fleck, A. D., Gaines, E. T., Juengst, H., Karlinsky, S., Miles, T. H., Murray, K. A., Quaid, N. R., Relkin, A. D., Roses, P.H., St. George-Hyslop, G. A., Sachs, B., Steinbock, E. F., Truschke, and A. B. Zinn. The clinical introduction of genetic testing for Alzheimer disease: An ethical perspective JAMA 277:832-836 (1997).
85. A. D., Roses. The Alzheimer's diseases. Current Biology 6:644-650 (1996).
86. K., Duff. Alzheimer transgenic mouse models come of age. Trends in Neurosciences 20:279-80 (1997).
87. M. L. Oster-Granite, D. L. McPhie, J. Greenan, and R. L. Neve. Age-dependent neuronal and synaptic degeneration in micetransgenic for the C terminus of the amyloid precursor protein. J. Neurosci. 16:6732-41 (1996).
88. J., Nalbantoglu, G., Tirado-Santiago, A. Lahsaini, J. Poirier, O., Gonsalvo, G. Verge, F., Momoli, S. A., Welner, G., Julien, J. P., Messicote, and M. L. Shapiro, Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor. Nature 387:500-505 (1997).
89. C. J., Heyser, E., Masliah, A., Samimi, I. L., Campbell, and L. H. Gold. Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain. Proc. Natl. Acad. Sci. 94:1500-1505 (1997).
90. P. K., Molsa, R. J., Marttila, and U. K., Rinne. Epidemiology of dementia in a Finnish population Acta Neural. Scand. 65:541-552 (1982).
91. L. S., Schneider, M. R., Farlow, V. W., Henderson, and J. M., Pogoda. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology 46:1580-84 (1996).